ClinicalTrials.gg
CompletedNCT03471130MT-8554 DQTUpdated Dec 17, 2025

Definitive QT Study With MT-8554

A Phase 1 interventional study of MT-8554 Low dose and MT-8554 High dose in Healthy Volunteer, sponsored by Tanabe Pharma America, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Provide written to participate in this study.
  • 2. Healthy and free from illness or disease as determined by medical history, physical examination (PE), laboratory, and other tests at Screening and Admission.
  • 3. Male and female subjects, aged 18 to 55 years (inclusive) at Screening.
  • 4. A body weight of ≥60 kg male and ≥50 kg female and a ranging from 18 to 30 kg/m2 (inclusive) at Screening.
  • 5. Subjects and partners agree to use throughout the study as detailed in the protocol.
  • 6. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

  • 1. Subjects with PR >240 ms, QRS ≥120 ms or interval (QTc) by Fridericia's correction >450 ms for males and >470 ms for females on the Screening , or any ECG abnormality, in the opinion of the Investigator.
  • 2. Subjects who have a history of cardiac disease or arrhythmias that can cause QTc prolongation.
  • 3. Family history of long or short QT syndrome, hypokalaemia, syncope, or Torsades de Pointes.
  • 4. Clinically significant (in the opinion of the Investigator) endocrine, thyroid, hepatic (including Gilbert's syndrome), respiratory, gastrointestinal (GI), renal (including estimated \<90 mL/min), cardiovascular disease, or history (within the last 2 years) of any significant psychiatric/psychotic illness disorder (including anxiety, depression and reactive depression).
  • 5. Clinically relevant abnormal medical history, physical findings, or laboratory values at Screening or Day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator.
  • 6. Previously having received MT-8554.
  • 7. Participation in more than 3 clinical studies involving administration of an IMP in the previous year, or any study within 12 weeks (or if relevant, 5 half-lives, whichever is longer) prior to the first dose.
  • 8. Presence or history of severe adverse reaction or allergy to any medicinal product that is of clinical significance.
  • 9. Subjects who have received any prescribed systemic or topical medication within 14 days (or if relevant, 5 half-lives; whichever is longer) prior to the first dose of IMP unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety. Subjects who have received slow release medicinal formulations considered to still be active within 14 days (or if relevant, 5 half-lives; whichever is longer) prior to the first dose administration will also be excluded unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety.
  • 10. Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days (or, if relevant, five half-lives; whichever is longer) prior to the first dose of IMP unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety. Occasional use of paracetamol (acetaminophen) for mild analgesia is permitted.
  • 11. Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days (or if relevant, 5 half lives; whichever is longer) prior to the first dose of IMP unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety.
  • 12. Subjects with (AST), alanine aminotransferase (ALT) ≥1.5× (ULN) or total or creatine kinase above the reference range at Screening or Day -1.
  • 13. Blood pressure (BP, supine) at Screening or Day -1 outside the range 90 to 140 mmHg (systolic) or 50 to 90 mmHg (diastolic); and pulse rate outside the range of 40 to 100 beats per minute (bpm), confirmed by repeat assessment. Evidence of postural hypotension defined as a decrease of >20 mmHg in systolic bp or >10 mmHg in diastolic bp between the supine and standing position, confirmed by repeat assessment.
  • 14. Tympanic body temperature at Day -1 that is outside the local reference range, confirmed by repeat assessment.
  • 15. Subjects who are pregnant (positive pregnancy test at Screening or Day -1) or lactating.
  • 16. Presence or history of lactose intolerance.
  • 17. Excessive consumption of food or drink containing caffeine, including coffee, tea, cola, energy drinks or chocolates (>5 cups of coffee or equivalent per day).
  • 18. Presence or history of drug abuse (as defined by [DSM-V] criteria), or a positive urine test for drugs of abuse at Screening or Day 1.
  • 19. Presence or history (in the last 2 years) of alcohol abuse, or intake of more than 28 units/224 g of alcohol weekly (for men) or 21 units/168 g of alcohol weekly (for women) or a positive breath test for alcohol at Screening or Day -1. One unit/8 g is equivalent to a half-pint (280 mL) of beer, 1 measure (25 mL) of spirits, or 1 glass (125 mL) of wine.
  • 20. Subjects who use tobacco or nicotine-containing products (cigarettes, snuff, chewing tobacco, cigars, pipes, e-cigarettes or nicotine replacement products) within 3 months prior to dosing, or positive urine cotinine test at Screening or Day -1.
  • 21. Test positive for surface antigen, hepatitis B core antibody, antibody, or (HIV) 1 \& HIV 2 antibodies at Screening.
  • 22. Donate ≥1 units of blood (450 mL) in the 3 months prior to Screening, plasma in the 7 days prior to Screening, in the 6 weeks prior to Screening, or intention to donate blood within 3 months after the last scheduled visit.
  • 23. Consumption of food or drink containing Seville oranges, cranberry, liquorice or grapefruit from 7 days prior to Day -1.
  • 24. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs; or which may jeopardise the subject in case or participation in the study. The Investigator should be guided by evidence of any of the following histories:

    1. Inflammatory bowel syndrome, gastritis, ulcers, GI or rectal bleeding
    2. Major GI surgery such as gastrectomy, gastroenterostomy, or bowel resection
    3. Clinical evidence of pancreatic injury or pancreatitis
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Low dose MT-8554 or placebo to match

    Low dose MT-8554

    Drug: MT-8554 Low dose · Drug: Placebo

  • Experimental
    High dose MT-8554 or placebo to match

    High dose MT-8554

    Drug: MT-8554 High dose · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in QTcF with placebo adjustment

    Time frame: Days 1 & 7

Secondary outcomes

  1. Proportion of subjects with changes to QTcF from Baseline exceeding >30ms

    Time frame: Days 1 & 7

  2. Proportion of subjects with changes to QTcF from Baseline exceeding >60ms

    Time frame: Days 1 & 7

  3. Change in Heart Rate compared to baseline

    Time frame: Days 1 & 7

  4. Change in PR Interval compared to baseline

    Time frame: Days 1 & 7

  5. Change in QRS duration compared to baseline

    Time frame: Days 1 & 7

Other outcomes

  1. Plasma concentration of MT-8554 with respect to time

    Time frame: Days 1 & 7

  2. Plasma concentration of metabolite with respect to time

    Time frame: Days 1 & 7

  3. Number of participants with treatment related adverse events

    Time frame: Days 1 to 9

07

Study locations

1 site
  • Investigational center
    City Name, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Oct 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
Mar 20, 2018
StartActual
Apr 23, 2018
Primary completionActual
Oct 19, 2018
CompletionActual
Oct 19, 2018
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03471130
Responsible party
Sponsor
First posted
Mar 20, 2018
Start date
Apr 23, 2018
Primary completion
Oct 19, 2018
Completion
Oct 19, 2018
Last update
Dec 17, 2025

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion